Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
adebrelimab
Description:
A monoclonal antibody that blocks the PD-L1 immune checkpoint and is studied as an anticancer immunotherapy.
Primary topic:
Lung Cancer Research Studies (24%)
Related topics:
Lung Cancer Research Studies (24%),
Cancer Immunotherapy and Biomarkers (12%)
Wikidata ID:
wiki/Q123575267
OpenAlex ID:
keywords/adebrelimab
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2022
·
Jie Wang
, Caicun Zhou
, et al.
·
The Lancet Oncology
·
496
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
2023
·
Jun Yin
, Jingnan Yuan
, et al.
·
Nature Medicine
·
108
PDF
Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial
2024
·
Dawei Chen
, Bing Zou
, et al.
·
EClinicalMedicine
·
51
Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis
2023
·
Shuxing Wang
, Yunshu Li
, et al.
·
Lung Cancer
·
40
PDF
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial
2022
·
Wanpu Yan
, Wen-Zhao Zhong
, et al.
·
Journal of Thoracic Oncology
·
37
Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
2023
·
Tianming Zhang
, Wenjun Li
, et al.
·
Frontiers in Immunology
·
32
PDF
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study
2023
·
Guanglei Chen
, Xi Gu
, et al.
·
eLife
·
31
Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
2022
·
Maojin You
, Ruijia Chen
, et al.
·
Frontiers in Pharmacology
·
22
First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis
2024
·
Lidan Yi
, Zhen Zhou
, et al.
·
Frontiers in Immunology
·
16
Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China
2024
·
Yunchun Long
, Hao Wang
, et al.
·
BMJ Open
·
13
PDF
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study
2025
·
Li Chen
, Wen‐Ya Wu
, et al.
·
癌症:英文版
·
12
PDF
Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial
2023
·
Youwen Zhu
, Kun Liu
, et al.
·
Therapeutic Advances in Medical Oncology
·
12
198P Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial
2024
·
Y. Cheng
, H. Wang
, et al.
·
ESMO Open
·
11
Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis
2023
·
Jincheng Du
, Xinyu Wang
, et al.
·
Heliyon
·
10
Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing
2023
·
Yena Gan
, Fenghao Shi
, et al.
·
Frontiers in Pharmacology
·
9
Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review
2024
·
Xiaoxuan Li
, Xinchi Luan
, et al.
·
Frontiers in Immunology
·
8
PDF
The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
2023
·
Bi-Cheng Wang
, Chen Fu
, et al.
·
Frontiers in Immunology
·
8
PDF
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
2026
·
Ting Li
, Teng Zhou
, et al.
·
Journal of Clinical Oncology
·
7
PDF
Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC: early results of a single-arm phase II clinical trial
2025
·
Yilin He
, Yuepeng Wang
, et al.
·
International Journal of Surgery
·
7
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
2025
·
Yingyi Li
, Yuqin Cao
, et al.
·
BMC Cancer
·
7
PDF
84P Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase III CAPSTONE-1 study
2023
·
Y. Cheng
, J. Wang
, et al.
·
Immuno-Oncology Technology
·
7
PDF
Comparison of efficacy and safety of first-line immunotherapy combined with chemotherapy in extensive-stage small cell lung cancer, a retrospective study
2025
·
Xue Dong
, Xiujing Yao
, et al.
·
Scientific Reports
·
6
PDF
Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge
2025
·
Huiwen Yang
, Linlin Yang
, et al.
·
Biologics
·
6
PDF
Neoadjuvant adebrelimab combined with chemotherapy (cisplatin/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS)
2025
·
Yanyang Liu
, Qian Huang
, et al.
·
BMJ Open
·
5
PDF
Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.
2024
·
Dawei Chen
, Aiqin Gao
, et al.
·
Journal of Clinical Oncology
·
5
PDF
Show more works
View as search
Works count:
222
Citation count:
1,058
Year
Topic
Type